Education
About Us
Working with TipRanks
Follow Us
ARS Pharmaceuticals (SPRY)
NASDAQ:SPRY
Earnings Data
Report Date
Aug 06, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.47Last Year’s EPS
-0.13Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 14, 2025
|% Change Since: 6.52%
|Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment|Positive
The earnings call reflected a strong market entry for Neffy with notable revenue growth and expanded insurance coverage. Strategic collaborations and a focus on pediatric dosing are positive, but high operating expenses and a net loss remain challenges. Prior authorization requirements continue to be a barrier, although they are decreasing.Company Guidance
During ARS Pharmaceuticals' first quarter 2025 earnings call, the company provided guidance highlighting several key metrics. The launch of neffy, a needle-free epinephrine treatment, has shown promising results with first-quarter U.S. net product revenue of $7.8 million. Neffy addresses a market potential of $3 billion in net sales, targeting approximately 6.5 million prescribed patients and an additional 13.5 million diagnosed patients without prescriptions. The company has achieved 57% commercial insurance coverage, up from 27% at the start of the year, and expects further demand growth with an upcoming direct-to-consumer campaign. The 1-milligram pediatric dose has also been approved and represents 23% of all epinephrine units dispensed in 2024. ARS is expanding its commercial reach through a collaboration with ALK-Abelló, aiming to target over 20,000 healthcare providers, including 9,000 pediatricians, to strengthen neffy's position as a leading epinephrine option. The company is also anticipating regulatory reviews and potential launches in the U.K., Canada, Japan, China, and Australia from mid-2025 through the first half of 2026.Neffy Launch and Market Potential
Neffy, the first needle-free epinephrine treatment, launched with a potential $3 billion net sales target in the U.S. market. It addresses significant unmet needs, gaining traction as a new standard of care.
Revenue Growth
Neffy generated $7.8 million in U.S. net product revenue in Q1 2025, with a total revenue of $8 million, indicating a strong market entry.
Insurance Coverage Expansion
Commercial insurance coverage for Neffy increased from 27% to 57%, with ongoing payer discussions expected to further increase coverage.
Successful Strategic Collaboration
ARS expanded a strategic collaboration with ALK-Abelló, enhancing commercial reach to over 20,000 healthcare providers, including 9,000 pediatricians.
Approval and Launch of Pediatric Dose
Neffy 1-milligram dose was approved by the FDA and launched for children, representing 23% of all epinephrine units dispensed in 2024.
Planned Direct-to-Consumer Campaign
A comprehensive DTC campaign, 'Hello neffy, Goodbye Needles', is set to launch, targeting a 95% reach of severe allergy patients and their caregivers.
SPRY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SPRY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 14, 2025 | $13.35 | $12.10 | -9.36% |
Mar 20, 2025 | $11.65 | $14.31 | +22.83% |
Nov 13, 2024 | $16.61 | $14.08 | -15.23% |
Aug 06, 2024 | $9.78 | $9.56 | -2.25% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does ARS Pharmaceuticals (SPRY) report earnings?
ARS Pharmaceuticals (SPRY) is schdueled to report earning on Aug 06, 2025, TBA Not Confirmed.
What is ARS Pharmaceuticals (SPRY) earnings time?
ARS Pharmaceuticals (SPRY) earnings time is at Aug 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SPRY EPS forecast?
SPRY EPS forecast for the fiscal quarter 2025 (Q2) is -0.47.